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Abstract

Author Manuscript

Background—Cardiovascular disease (CVD) imparts a heavy economic burden on our health
care system. Evidence regarding the long-term costs following comprehensive CVD screening is
limited.
Objective—We calculated 10-year health care costs for 6,814 asymptomatic participants enrolled
in the National Institutes of Health–National Heart, Lung, and Blood Institute–sponsored MultiEthnic Study of Atherosclerosis (MESA).
Methods—Cumulative 10-year costs for CVD medications, office visits, diagnostic procedures,
coronary revascularization, and hospitalizations were calculated from detailed follow-up data.
Costs were derived using Medicare nationwide and zip code–specific costs, inflation-corrected,
discounted at 3%/year, and presented in 2014 U.S. dollars.

Author Manuscript

Results—Risk factor prevalence increased dramatically and, by 10 years, diabetes, hypertension,
and dyslipidemia was reported in 19%, 57%, and 53%, respectively. Self-reported symptoms (i.e.,
chest pain or shortness of breath) were common (~40% of enrollees). At 10-years, approximately
one-third of enrollees reported having an echocardiogram or exercise test while 7% underwent
invasive coronary angiography. These utilization patterns resulted in 10-year health care costs of
$23,142. The largest proportion of costs was associated with CVD medication use (78%).
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Approximately $2 of every $10 was spent for outpatient visits and diagnostic testing among the
elderly, obese, those with a high-sensitivity C-reactive protein >3 mg/l or coronary artery calcium
score (CACS) ≥400. Costs varied widely from <$7,700 for low-risk (Framingham Risk Score
[FRS] <6%, 0 CACS, and normal glucose measurements at baseline) to >$35,800 for high-risk
(persons with diabetes, FRS ≥20%, or CACS ≥400) subgroups. Among high-risk enrollees, CVD
costs accounted for $74 of the $155 million consumed by MESA participants.
Conclusions—Longitudinal patterns of health care resource use following screening reveal new
evidence on the economic burden of treatment and testing patterns not previously reported.
Maintenance of a healthy population has the potential to markedly reduce the economic burden of
CVD among asymptomatic individuals.
Keywords

Author Manuscript

asymptomatic; cardiovascular disease screening; economics; long-term follow-up

Introduction

Author Manuscript

In the United States, nearly 1 in 3 (~80 million) adults have some form of cardiovascular
disease (CVD), which imparts a heavy economic burden, including estimated direct costs of
approximately $444 billion (1–4). The CVD costs of care are continuing to rise, with the
current costs for treatment accounting for nearly $1 of every $6 spent on health care (2). The
evidence to date on the economic implications of CVD screening is less well developed.
Screening for CVD has the potential to improve clinical outcomes through effective
detection of CVD risk and to intensify preventive efforts among asymptomatic individuals.
Other forms of screening, such as for lung, breast, and colon cancer, form the basis for
preventive health, with robust economic evidence and documentation of the expense of
downstream disease states (5). Heretofore, the evidence base on the impact of CVD testing
on long-term health care expenditures among asymptomatic, apparently healthy individuals
has been unknown. The aim of this analysis was to estimate 10-year CVD costs based on
detailed resource consumption patterns collected within the National Institutes of Health
(NIH)–National Heart, Lung, and Blood Institute (NHLBI)–sponsored Multi-Ethnic Study
of Atherosclerosis (MESA) (6,7).

Methods
MESA Enrollment Criteria

Author Manuscript

Enrollment criteria and CVD testing procedures for the MESA have been previously
reported in detail (6,7). In brief, a total of 6,814 asymptomatic, apparently healthy
individuals (age range: 44 to 84 years) were enrolled. This substudy was approved by the
MESA policy and publications committee and undertaken with a data use agreement
between Emory University and the University of Washington.
Collection of Baseline Traditional Risk Factors
During the baseline visit, participants were queried as to the history of cardiac risk factors.
Self-reported history of diabetes, hyperlipidemia, and hypertension, a family history of
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CVD, and smoking history was recorded. At this time, lipids, glucose, and blood pressure
were measured; details of the methodology have been published (6,8). A Framingham Risk
Score (FRS) was calculated on each enrollee, including categories of 10-year predicted risk
of <6%, 6% to 9.9%, 10% to 19.9%, and ≥20% (9). Use of a total of 46 drugs classes, such
as sulfonylurea, beta-blocker, and calcium-channel blocker therapies, were collected in
MESA.
Nontraditional CVD Testing

Author Manuscript

At the baseline visit, MESA enrollees had measurement of high-sensitivity C-reactive
protein (hsCRP) using standardized methodology (10). High- and low-risk hsCRP was
defined as >3 and ≤3 mg/dl, respectively (11). At the baseline visit, all participants
underwent coronary artery calcium scoring (CACS). The protocol and methods for CACS
were performed using standardized methodologies (6,7,10). For this analysis, CACS was
categorized as 0, 1 to 10, 11 to 99, 100 to 399, 400 to 999, and ≥1,000, respectively.
Data Collection of Socioeconomic Factors
During the baseline visit, detailed socioeconomic status data was collected including:
marital status; employment status; highest level of education achieved; household income;
and health insurance coverage. These variables were candidates for covariate adjustment in
the cost models, as they are established determinants of health care utilization.
Follow-Up Methodologies

Author Manuscript
Author Manuscript

MESA collected detailed follow-up hospitalization, medication usage, and varied patterns of
resource consumption throughout follow-up. In total, MESA participants returned for a total
of 4 additional clinic examinations every 2 years. During each follow-up visit, a detailed
history of intercurrent office visits, CVD diagnostic (e.g., exercise stress testing) and
invasive (diagnostic coronary angiography and coronary revascularization) procedures, CVD
hospitalizations, as well as current and revised prescribed CVD medications was
ascertained. Medicare nationwide mean payments for diagnostic procedures, coronary
revascularization, and hospitalizations are provided in Online Appendix 1. CVD medications
included medications for hypertension, diabetes, and dyslipidemia such as diuretic agents,
beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, insulin, and statins. Antiischemic and heart failure (HF) medication usage was also collected (e.g., nitrates, ACE
inhibitors). In the years when an in-person clinic examination was not scheduled,
participants completed follow-up information through a detailed telephone interview.
Similar to the clinic visit, data on medication, procedures, and hospitalizations was collected
annually. Specific questions on changes in drug therapy and intensification or reduction in
dosing were collected annually. During each follow-up contact, an enrollee was queried as to
whether a new diagnosis of hypertension, diabetes, or dyslipidemia was assigned by their
overseeing health care provider. In year 1 of follow-up, participants were queried as to
whether they had discussed their MESA test results with their primary care physician.
MESA investigators did not provide treatment or procedural guidance based on test findings.
Data on CVD hospitalization was collected similar to the procedural and visit data. Angina
or HF hospitalization, coronary revascularization, acute myocardial infarction (MI), or
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stroke underwent a detailed event adjudication by the MESA morbidity and mortality
committee, as detailed in an online manual (12). The timing for MI, HF, angina, coronary
revascularization, and resuscitated cardiac arrest was collected. During follow-up, all
enrollees were queried as to new-onset chest pain during the preceding year of follow-up
and adjudicated angina was defined as an episode of ischemic pain, tightness, pressure, or
discomfort in the chest, arm, or jaw, when co-occurring with a prescribed anti-ischemic
therapy, documented angiographic obstructive coronary artery disease, an ischemic
electrocardiogram, or imaging abnormality. Each enrollee was also queried with regard to
the presence of shortness of breath symptoms. The criteria for adjudicated, symptomatic HF
was documented HF symptoms and receiving treatment (with diuretic agents, vasodilator
agents, beta-blockers, or ACE inhibitors) or imaging evidence of a dilated left ventricular or
reduced left ventricular ejection fraction.

Author Manuscript

CVD Health Care Costs

Author Manuscript
Author Manuscript

The Centers for Medicare and Medicaid Services pharmacy charges (zip code–specific for
each site) and nationwide reimbursement rates for office visits, CVD procedures, and
hospitalizations were collected. Common prescribing doses were examined and aggregated
by drug class (13). Based on the common prescribing doses, median drug pricing was
derived using the site- or zip code–specific, online drug pricing. Online Appendix 2 provides
a range of costs for CVD medications across the participating sites. Generic pricing for
antihypertensive (e.g., diuretic agents, ACE inhibitors, beta-blockers), cholesterol-lowering
(e.g., statins), and diabetes (e.g., metformin) drugs were collected (Online Appendix 3). All
fees were derived by the year of reported use during the 10 years of follow-up. Costs for
outpatient services were derived from the Outpatient Prospective Payment amounts based on
Healthcare Common Procedure Codes using the Outpatient PC Pricer system for nationwide
mean fees (14). A similar approach was applied to define in-hospital procedures (PC Pricer
Prospective Payment System estimator) (15). Payment codes included: diagnosis related
groups 66 to 69, 222 to 223, 232, 236 to 238, 280 to 285, 293, 311, 313; ambulatory
payment classifications 96, 99, 336, 337, 602; and current procedural terminology 80053,
80061, 83519, 85380, 85384, 86140, 93015, 93350, 93454 to 93459. An MI hospitalization
that occurred within 1 week of a percutaneous coronary intervention or coronary artery
bypass surgery was assigned the relevant Medicare payment. Hospital costs varied and were
higher when associated with complications. We applied mean costs, for example, for acute
MI. When a range of hospital costs for a given admission were applied, our results did not
vary. All costs were inflation-adjusted using the medical care component of the consumer
price index (16). The unit cost is given in 2014 U.S. dollars. Costs were discounted at 3%/
year to reflect the lower economic value of deferred expenses. When a cost was assigned to
a given year of follow-up, discounting was based on the remaining years of follow-up
through 10 years. As enrollment occurred from 2000 to 2002, patient-specific costs varied
by the year of follow-up (e.g., a year 1 cost may be from 2001 to 2003 for a given patient).
Costs for medications, outpatient visits, procedures, coronary revascularization, and
hospitalizations were summed for each MESA enrollee. Nonsurviving enrollees had costs
accumulated until their deaths.
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All analyses were performed on MESA-approved and locked SAS files. Descriptive
statistics (mean ± 95% confidence interval [CI] or percentage for continuous and categorical
variables) were recorded. Chi-square and Student t-tests were used to compare MESA
subgroups. We plotted the cumulative (unadjusted) costs through 10 years of follow-up
aggregated by costs for CVD medications, outpatient visits, diagnostic procedures, coronary
revascularization, and hospitalization. Unadjusted costs for CVD medications, outpatient
visits, diagnostic procedures, coronary revascularization, and hospitalizations were plotted
for women and men by age, FRS, CACS, and hsCRP subgroups, respectively.

Author Manuscript

A multivariate linear regression model was calculated to identify predictors of elevated 10year health care costs. We log-transformed the 10-year cost to normalize the distribution of
the values. The primary analysis was undertaken using the log-transformed cost variable for
evaluation of statistical significance. An additional linear regression model using
(nontransformed) cost as the dependent measure was used to derive adjusted cost values
from the unstandardized beta coefficients. Socioeconomic covariates in the model were
education, income, and health insurance coverage. From the linear regression model, the
model r2 was calculated. Predicted costs were then compared across MESA subgroups (i.e.,
by CACS, FRS, age, BMI, hsCRP, hypertension, and diabetes). We then defined: a low-risk
subgroup as those with a low-risk FRS, CACS = 0, and normal glucose values (n = 1,182); a
high-risk subgroup as those with a high-risk FRS, CACS ≥400, or diabetes (n = 2,520); and
a very high-risk subgroup with a high-risk FRS, CACS ≥400, and diabetes (n = 126).
Among these subgroups, we plotted cumulative costs and 95% CIs for women and men. We
then calculated the proportion of total costs for CVD medications, diagnostic procedures,
outpatient visits, coronary revascularization, and hospitalizations. In a secondary analysis,
we applied the lowest-cost, generic pricing for hypertension, dyslipidemia, and diabetic
medication costs (Online Appendix 3). Cost savings were calculated as the difference
between brand name and generic pricing.

Author Manuscript

Statistical analysis was performed using SAS version 9.4 (SAS Institute, Cary, North
Carolina) and IBM SPSS version 24.0 (IBM, Armonk, New York).

Results
Socioeconomic Characteristics of the MESA (Table 1)

Author Manuscript

Among the 6,814 MESA enrollees, the median age was 62 years, 53% were women, with 10
years of follow-up data reported. Enrollment included diverse representation of AfricanAmerican (28%), Chinese (12%), and Hispanic (22%) individuals. Only 35% of MESA
participants completed a college education with a bachelor’s degree or higher, and only 38%
were employed full-time. Approximately one-half of MESA enrollees had a family income
<$40,000/year. Of the MESA participants, 69% had private health insurance and 93%
reported a doctor’s office or clinic as their regular source of medical care.
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Risk Factor Diagnosis and Treatment on the Baseline Visit (Table 2)
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At the baseline examination, 39%, 37%, and 11% of enrollees, respectively, reported a
history of hypertension, dyslipidemia, and diabetes. An abnormal fasting glucose or diabetes
was reported in 26% of MESA enrollees. Similarly, 45% of enrollees met criteria for
hypertension on the baseline examination. Approximately 60% of MESA participants were
on a CVD-preventive medication for hypertension, dyslipidemia, or diabetes at the baseline
visit. Of the MESA enrollees, 55% reported that they discussed findings from their baseline
examination with their primary care physician. Nearly 60% of enrollees had an intermediatehigh FRS. A high-risk hsCRP >3 mg/l occurred in 36% of participants, and 10% had a
CACS ≥400.
10-Year Cumulative Diagnoses of Diabetes, Hypertension, and Dyslipidemia (Table 3)

Author Manuscript

At the index examination, 10%, 45%, and 37%, respectively, of MESA participants had
diabetes, hypertension, and dyslipidemia. During follow-up, there was a graded increase in
the cumulative incidence of diabetes, hypertension, and dyslipidemia. Cumulative 10-year
rates of diabetes, hypertension, and dyslipidemia were 19%, 57%, and 53%, respectively.
10-Year Procedural Utilization Data (Table 4)
By 10 years of follow-up, approximately one-third of MESA enrollees underwent an
echocardiogram or exercise test. At the end of follow-up, 70% of MESA participant had one
or more noninvasive diagnostic procedures. The cumulative 10-year rate of invasive
angiography was 6.9%.
10-Year Self-Reported Chest Pain or Dyspnea Symptoms (Table 5)

Author Manuscript

The cumulative rate of self-reported chest pain at 10 years was 39%, whereas the 10-year
rate of adjudicated angina was 9.6%. Of note, 79% and 39% of MESA enrollees with and
without angina, respectively, underwent exercise testing (p < 0.0001). Similarly, 55% and
4% of MESA enrollees with and without angina underwent invasive coronary angiography
during 10 years of follow-up (p < 0.0001). The odds of invasive angiography were 8-fold
higher (95% CI: 5.8 to 11.4) among patients experiencing an acute MI or resuscitated
cardiac arrest during follow-up (p < 0.0001). Nearly one-third of individuals undergoing
invasive coronary angiography also had documented coronary revascularization (including
54 coronary bypass surgeries and 79 percutaneous coronary interventions).

Author Manuscript

The cumulative rate of self-reported shortness of breath at 10 years was 43%, whereas the
10-year rate of adjudicated HF was 6.9%. For those with and without HF symptoms, 77%
and 35% of enrollees, respectively, reported having an echocardiogram performed during
follow-up (p < 0.0001).
10-Year CVD Costs (Figure 1)
All costs presented in Figures 1 and 2 are unadjusted. The mean cumulative 10-year health
care costs were $23,142 and summed to >$155 million for all enrollees. Cumulative health
care costs ranged from $0 to $274,582; with 10th, 25th, 50th, 75th, and 90th percentile costs,
respectively, of $592, $2,026, $13,349, $33,026, and $56,824. Over time, CVD medication

J Am Coll Cardiol. Author manuscript; available in PMC 2019 March 13.

Shaw et al.

Page 7

Author Manuscript

costs represented a growing proportion of cumulative costs. At 10 years of follow-up, 78%
of cumulative costs were associated with CVD medication usage. When generic pricing was
applied to treatment for diabetes, hypertension, and dyslipidemia, total costs for CVD
medications were reduced by ~$45 million, representing a 36.3% cost savings. By applying
generic pricing, the proportional costs for CVD medications would be reduced to 71% of the
total CVD health care costs. The proportion of cumulative costs were 4.3%, 8.6%, 5.4%, and
3.3%, respectively, for outpatient visits, diagnostic procedures, coronary revascularization,
and CVD hospitalizations.

Author Manuscript

Costs varied widely and increased with advancing age for women and men (Figure 2A).
MESA participants <65 years of age had much lower health care costs. Similarly, costs
increased from low- to high-risk FRS subgroups (Figure 2B). Across the FRS subgroups,
women had higher cumulative costs. Women were older across FRS subgroups by 6, 9, 7,
and 2 years for low, average, intermediate, and high FRS enrollees, respectively (p <
0.0001).
A similar pattern of health care costs was noted across low- to high-risk CACS (Figure 2C),
and hsCRP (Figure 2D) subgroups. Among those with a high-risk hsCRP, new diagnoses for
dyslipidemia, hypertension, and diabetes contributed to higher CVD medication costs. For
those with a high-risk hsCRP, the rate of diagnosis for hypertension, diabetes, and
dyslipidemia increased 1.7-, 2.9-, and 4.9-fold, respectively, over the 10 years of follow-up.
Multivariate Linear Regression Model Estimating 10-Year Health Care Costs (Central
Illustration)

Author Manuscript

We then performed multivariate linear regression modeling to identify significant estimators
of 10-year CVD health care costs. The results from a multivariate linear regression using
log-transformed and nontransformed cost as the dependent variable reveal similar findings
(Online Appendix 4). The Central Illustration plots show adjusted costs. Cumulative costs
were high for those with impaired fasting glucose or diabetes. For those with impaired
fasting glucose, adjusted costs were $11,449, whereas those with untreated and treated
diabetes had 10-year CVD costs of $5,567 and $12,274. Using this analysis, a CACS of 400
to 999 contributed $15,511 in higher costs, and an additional $3,668 in higher costs was
estimated for those with a CACS ≥1,000. By comparison, a high-risk hsCRP >3 mg/l added
$4,948 to cumulative health care costs.
Proportional Costs for CVD Medications, Visits, Procedures, and Hospitalizations

Author Manuscript

Table 6 reports the proportion of 10-year health care costs associated with CVD
medications, diagnostic procedures, outpatient visits, coronary revascularization, and CVD
hospitalization. For all MESA enrollees, CVD medications encumbered the highest
proportion of 10-year costs of care; especially for persons with diabetes (87%) and
dyslipidemia (90%). The elderly, obese, and those with a high-risk hsCRP > 3 mg/l and a
CACS ≥400 had higher proportional costs related to diagnostic procedures and outpatient
visits. Approximately 5% of costs for MESA enrollees with a CACS ≥400 were attributed to
coronary revascularization. Less than 5% of 10-year health care costs were attributable to
CVD hospitalization.
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Low- and High-Cost Subgroups
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A total of 1,182 MESA enrollees were categorized as low risk (0 CACS, a low FRS, and
normal glucose values at baseline) with cumulative 10-year (mean) costs of $7,008, albeit
higher in women due to their older age and elevated costs for outpatient visits and CVD
medications. Total costs associated with low-risk status were $8.3 million, or 5.2% of the
total $155 million for all MESA enrollees. By comparison, among the 2,520 high-risk
participants (CACS ≥400, diabetes, or a high-risk FRS), 10-year costs of health care were
$37,732 for women and $35,814 for men. Total costs associated with high-risk status were
$74 million, or 48% of the $155 million total for all MESA enrollees.

Discussion
Author Manuscript

The NIH-NHLBI–sponsored MESA is a landmark investigation reporting on the long-term
effectiveness of traditional and nontraditional risk markers for prediction of major CVD
events (7,10). Although many risk markers have proven effectiveness at stratifying
populations, estimating risk alone is insufficient to describe the clinical burden of diagnosis
and treatment for high-risk subsets. Limited information is available on the follow-up
resource consumption and cost patterns among asymptomatic individuals following a
detailed screening examination collecting measurements of CVD risk factors and
nontraditional risk markers, such as with hsCRP and CACS (17–20). Our findings are
consistent with prior estimates that there is an increasing economic burden of CVD over
time, which is projected to increase to $1.1 trillion in the United States by 2035 (21). This
pattern of accelerating health care costs within the MESA reveals that individuals who are
screened today will experience suspected coronary artery disease symptoms and new
diagnoses prompting more intensive treatment and frequent use of diagnostic procedures.

Author Manuscript

Cost Findings among MESA Subgroups
Our MESA analysis examining resource consumption patterns reveals dramatic and
surprising differences in CVD costs across varied MESA subgroups. We identified a highrisk population cohort with a high FRS, CACS ≥400, or diabetes that consumed nearly onehalf of the estimated $155 million for CVD health care costs during the 10 years of followup. By comparison, a low-risk population cohort (with normal glucose values, no detectable
CACS, and a low risk FRS) consumed only 5% of the CVD health care costs over 10 years.
These results are similar to recent findings from the Chicago Heart Association Detection
Project noting that low CVD risk individuals had decidedly lower 5-year Medicare costs
(22).

Author Manuscript

Moreover, women often had higher CVD costs, in large part related to their risk factor
burden and advanced age compared with men. This relationship between women and men
was most apparent when comparing across FRS subgroups where, in low to intermediate
FRS subgroups, 10-year costs were ~$10,000 higher among average to intermediate risk
women. Numerous reports have challenged the accuracy of the FRS and proposed an
underestimation of risk, particularly associated with aging for women. This factor led to
comparisons across any FRS subgroup of women having higher CVD costs and more
intensive resource consumption patterns compared with men (23).
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We also reported a lack of association between race and ethnicity as a primary driver of
increased CVD costs. Many reports note the high burden of CVD risk factors and
comorbidities that increase CVD event risk among racial and ethnically-diverse patient
populations (24). Our analysis revealed that the addition of income, insurance, and education
attenuated the impact of race and ethnicity as a significant driver of health care. These data
further support that socioeconomic factors influence resource consumption patterns for
many priority populations, including MESA enrollees of diverse race and ethnicity (23).
Moreover, policies focusing on equitable access to preventive management not only reduce
health care disparities, but may also influence the economic burden of CVD care among atrisk minority populations.

Author Manuscript

Another surprising finding is the high costs (~$5,000) associated with high-risk hsCRP.
Certainly, the epidemiological data support an elevated CVD risk that would increase
hospitalization and revascularization costs (25–27). Analyses also detailed higher costs for
CVD medications among those with hsCRP >3 mg/l, which was likely influenced by trial
evidence of therapeutic risk reduction with statin therapy (28).
A final example is the high rate of self-reported chest pain and shortness of breath in this
initially apparently healthy, asymptomatic population. Nearly 1 in 10 MESA enrollees
reported symptoms that prompted a high rate of diagnostic procedural use when compared
with those without such symptoms. This association suggests a heavy burden of suspected
symptoms, which may underlie the high rates of diagnostic procedures observed over the
past several decades (29).
Policy Implications for Investing in Screening of Apparently Healthy Populations

Author Manuscript
Author Manuscript

As health care systems embark on population health strategies, the cost estimates from
MESA may provide insight into the cost implications of early screening and targeted
preventive programs. From our analysis, we capture a low-risk subgroup with decidedly
lower long-term CVD costs when compared with higher-risk MESA subgroups. It is
possible that an investment in preventive health programs could be economically
advantageous if a sizeable proportion of enrollees maintain their low-risk status for many
years. Moreover, depending on the success of preventive programs, investments could be
balanced by reduced health care costs for the low-risk patients who require minimal clinical
care. As CVD medications encumbered the highest proportional costs, a focus on behavioral
or community-wide policies and programs to enhance lifestyle changes may reduce the need
(and thus the costs) for CVD medications. There should also be an aim on more widespread
use of lower-cost treatments, such as aspirin, to reduce CVD risk while adding minimally to
CVD costs (30).
Moreover, implementation of community or health system policies may become more
palatable if economic advantages, such as that estimated within MESA, were realized in
long-term CVD costs of care. In a recent example, New York City health policy initiatives
on improving healthy eating behaviors and tobacco control were associated with reductions
in CVD mortality (31). The dramatic differences in cost among MESA subgroups provide
insight into the substantive health care costs that could be averted by reducing the burden of
risk factors (i.e., CACS) and preventing atherosclerotic disease development.
J Am Coll Cardiol. Author manuscript; available in PMC 2019 March 13.
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MESA Limitations
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Importantly, contractual agreements with private payers generally have higher payment rates
than that of Medicare. Thus, for the nearly one-quarter of MESA enrollees who are not yet
eligible for Medicare, costs were underestimated. Although rigorously collected data were
ascertained on utilization of health care services, only Medicare data was used in our
analyses. Limited diagnostic test results were available. The MESA adjudication process
was detailed and provided for ascertainment of CVD hospitalizations and events, as well as
symptom data. Data are not available to compare the effectiveness of various screening
strategies, as all enrollees underwent a battery of laboratory and imaging procedures.

Conclusions
Author Manuscript

The longitudinal patterns of health care resource use following traditional and nontraditional
CVD testing within the MESA reveal new evidence on the long-term economic burden of
follow-up treatment and testing patterns. The economic needs of the adult population with
traditional and nontraditional CVD risk markers exceeded $155 million in the MESA. These
data illustrate the unique contributions to elevated cost, and the targeted economic burden of
various risk factors and markers on total health care costs. Identification of low-risk
populations that maintain a healthy weight, glucose, blood pressure, and cholesterol have
markedly reduced health care costs. High-risk subgroups with diabetes, a high FRS, or a
CACS ≥400 have up to 15-fold higher costs for health care, and targeted early screening and
intervention programs could offset the elevated long-term costs for asymptomatic
populations.

Abbreviations and Acronyms
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BMI

body mass index

CACS

coronary artery calcium score

CVD
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PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE
Among patients screened for CVD, those in high-risk subgroups have up to 15-fold
greater costs for health care over the following decade.
TRANSLATIONAL OUTLOOK
Further studies are needed to confirm whether more carefully targeted screening and
intervention programs for asymptomatic populations could reduce the elevated resource
utilization and costs during long-term follow-up.
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Figure 1. Cumulative Mean Per-Patient CVD Costs for Medications, Diagnostic Procedures,
Outpatient Visits, Coronary Revascularization, and Hospitalization among 6,814 MESA
Participants

At each year of follow-up, the mean per-patient cost values for medications, visits,
diagnostic procedures, coronary revascularization, and hospitalization are reported. The
mean value at each year of follow-up is reported above the cumulative total costs. All cost
values are rounded to the nearest whole number. CVD = cardiovascular disease; MESA =
Multi-Ethnic Study of Atherosclerosis.
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Figure 2. Follow-up CVD Costs* for Medications, Diagnostic Procedures, Outpatient Visits,
Coronary Revascularization, and Hospitalization Among MESA Subgroups

(A) Follow-up CVD costs for medications, diagnostic procedures, outpatient visits, coronary
revascularization, and hospitalization among 6,814 MESA participants across age and sex
subgroups. Costs are reported by sex, as data support variable cost patterns among women
and men. For Figure 2, the cumulative costs by subgroups of medications, visits, diagnostic
procedures, coronary revascularization, and hospitalization are reported. The cumulative
costs across the age ranges support higher cost/resource consumption patterns. (B)
Cumulative follow-up CVD costs* for medications, diagnostic procedures, outpatient visits,
J Am Coll Cardiol. Author manuscript; available in PMC 2019 March 13.
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coronary revascularization, and hospitalization among 6,814 mesa participants across
Framingham Risk Score (FRS) subgroups of women and men. The cumulative costs across
the FRS subgroups support higher cost/resource consumption patterns among higher-risk
individuals. The presented costs are unadjusted consumption patterns among older
individuals. The presented costs are unadjusted. (C) Follow-up CVD costs* for medications,
diagnostic procedures, outpatient visits, coronary revascularization, and hospitalization
among 6,814 MESA participants across CACS subgroups of women and men. The
cumulative costs across the CACS subgroups support higher cost/resource consumption
patterns among individuals with more extensive CAC. Please note that this x-axis extends
through $60,000 versus $40,000 for the age, FRS, and hsCRP analyses. The presented costs
are unadjusted. (D) Follow-up CVD costs* for medications, diagnostic procedures,
outpatient visits, coronary revascularization, and hospitalization among 6,814 MESA
participants across hsCRP subgroups of women and men. The cumulative costs among lowand high-risk hsCRP subgroups report slightly higher cost/resource consumption patterns
within these higher risk individuals. Noteworthy is the higher costs associated with
medications for those individuals with high-risk hsCRP. The presented costs are unadjusted.
CACS = coronary artery calcium score; FRS = Framingham Risk Score; hsCRP = highsensitivity C-reactive protein. Other abbreviations as in Figure 1.
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Figure 3. Cumulative Follow-Up CVD Health Care Costs Among MESA Subjects with Low- and
High-Risk Findings

Cumulative (unadjusted) follow-up CVD health care costs (with 95% confidence intervals,
dotted lines) are shown for low-risk (n = 1,182 with low-risk FRS, CACS = 0, and normal
glucose values) and high-risk findings (n = 2,520 with CACS ≥400, diabetes, or high-risk
FRS). A subset of very high-risk subjects, defined as diabetic patients with a high-risk FRS
and CACS ≥400 (n = 126) is plotted as an insert. Abbreviations as in Figures 1 and 2.
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Central Illustration. Adjusted 10-Year Health Care Costs by Traditional and Nontraditional
CVD Risk Factors

Author Manuscript

We first log-transformed 10-year total costs and performed a multivariate linear regression
(Model r2 = 0.41; p < 0.001). So that adjusted costs might be presented, results from a
multivariate linear model using the log-transformed dependent variable of 10-year total costs
are also shown (Model r2 = 0.35; p < 0.001). From this latter model, we present the
predicted, unique costs associated with each variable and/or subgroup. For example, MESA
enrollees with an impaired fasting glucose had $11,449 higher 10-year costs compared with
those with normal glucose values. Moreover, a participant with untreated diabetes at the
index evaluation had an additional $5,567 in ten-year health care costs compared with
participants with an impaired fasting glucose. Finally, the 10-year health care costs were
highest for those with treated diabetes ($29,290). Costs are ranked from highest to lowest.
When added to the model, MESA racial/ethnic subgroups had lower costs of CVD; with
black, Hispanic, and Chinese participants having $832, $619, and $1,666 lower adjusted 10year costs (p = 0.46); however, this is not statistically significant. Similarly, enrollees on
Medicare, Medicaid, or with private insurance had predicted costs of $2,264 (p = 0.006),
$562 (p = 0.63), and $719 (p = 0.30), respectively. BMI = body mass index; CAC =
coronary artery calcium; CRP = C-reactive protein; CVD = cardiovascular disease; FRS =
Framingham Risk Score; MESA = Multi-Ethnic Study of Atherosclerosis.
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Socioeconomic Characteristics That Influence Health Care Utilization
N = 6,814
Age deciles (yrs)
45–54

28.6

55–64

27.7

65–74

29.6

75–84

14.2

Sex
Women

52.8

Men

47.2

Author Manuscript

Race
African American

27.8

Chinese

11.8

Hispanic

22.0

Caucasian

38.5

Marital status
Married

60.6

Widowed

13.1

Divorced

13.6

Separated

3.7

Not married

8.2

Education

Author Manuscript

<9th grade

11.0

Grades 9–11

7.0

High school

18.2

Some college

28.5

Bachelor’s degree

17.3

Graduate school

18.0

Employment

Author Manuscript

Homemaker

11.5

Full-time

38.4

Part-time

8.6

Unemployed

2.3

Retired

38.1

Family income†
<$20,000

23.9

$20,000–$29,900

13.6

$30,000–$39,900

13.1

J Am Coll Cardiol. Author manuscript; available in PMC 2019 March 13.

Shaw et al.

Page 21

N = 6,814
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$40,000–$49,900

9.8

$50,000–$74,900

17.0

$75,000–$99,900

9.1

≥$100,000

13.5

Health insurance
Private

69.3

Medicare

35.9

Medicaid

7.0

None

9.0

Regular source of medical care

Author Manuscript

Doctor’s office or clinic

92.8

Hospital or emergency department

3.1

Values are %.

*

Variables include a nonresponse category and do not sum to 100%. In some cases, multiple responses are included, such as for health insurance.
Due to rounding, not all categories sum to 100%.

†

Income ranges were based on 2000-2002 statements based on the year of enrollment.
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Baseline FRS, Traditional and Nontraditional Risk Factor Measurements, Preventive Medication Usage, and
Follow-Up Physician Discussions Regarding MESA Findings
Self-reported
Dyslipidemia

37.3

Hypertension

39.3

Diabetes

11.3

BMI (kg/m2)

28 (25–31)

Examination diabetes categories
Treated diabetes

10.0

Untreated diabetes

2.6

Impaired fasting glucose

13.8

Author Manuscript

FRS – 10-yr predicted risk
<6%

24.1

6–9.9%

17.4

10–19.9%

28.6

≥20%

29.9

Preventive medication use
Aspirin (regular use ≥3 times/week)

23.9

Hypertension

33.3

Lipid-lowering

16.2

Diabetes

9.8

None

43.4

Author Manuscript

hsCRP
≤3 mg/l

63.9

>3 mg/l

36.1

CACS
0

50.1

1–10

7.5

11–99

18.9

100–399

13.6

400–999

6.2

≥1,000

3.8

Author Manuscript

Discussion of MESA findings with primary care physician

54.8

Values are % or median (interquartile range).
BMI = body mass index; CACS = coronary artery calcium score; FRS = Framingham Risk Score; hsCRP = high-sensitivity C-reactive protein;
MESA = Multi-Ethnic Study of Atherosclerosis
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Table 3

Author Manuscript

Cumulative 10-Year Proportion of Incident Diabetes, Hypertension, and Dyslipidemia Among MESA
Participants

Author Manuscript

Yrs of Follow-Up

Diabetes

Hypertension

Dyslipidemia

Index

10.0

44.9

37.3

1

13.2

46.5

39.7

2

13.8

47.6

42.5

3

15.3

49.2

43.9

4

15.2

50.7

45.7

5

16.0

52.0

47.5

6

16.6

53.0

48.6

7

17.4

54.2

50.0

8

18.0

55.2

51.0

9

18.9

56.1

52.1

10

19.3

57.0

52.8

Values are %.
MESA = Multi-Ethnic Study of Atherosclerosis
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Table 4

Author Manuscript

Cumulative 10-Year Proportion of Follow-Up for Diagnostic Testing Among MESA Participants

Author Manuscript

Yrs of Follow-Up

Echocardiogram

Exercise Test

Invasive Angiography

No Follow-Up Testing

1

5.9

5.4

0.9

88.2

2

9.3

7.6

1.5

81.2

3

13.6

12.1

2.2

70.6

4

16.5

15.2

3.0

65.1

5

20.6

19.3

3.8

56.2

6

23.6

22.3

4.5

51.1

7

27.4

25.6

5.2

44.3

8

30.8

28.1

5.7

40.3

9

33.5

30.5

6.4

35.8

10

35.6

32.1

6.9

29.5

Values are %.
MESA = Multi-Ethnic Study of Atherosclerosis
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Table 5

Author Manuscript

Annual Proportion of Self-Reported Chest Pain and Shortness of Breath

Author Manuscript

Yrs of Follow-Up

Chest Pain

Shortness of Breath

Index

0.0

0.0

1

9.8

12.9

2

10.7

14.3

3

10.6

14.6

4

10.3

15.1

5

11.2

14.9

6

9.6

13.3

7

9.8

13.3

8

8.8

14.8

9

10.5

16.3

10

8.9%

15.1%

Cumulative rate

38.7

43.3%

Adjudicated rate

9.6 with angina

6.9 with heart failure

Values are %. Across all Multi-Ethnic Study of Atherosclerosis participants, the cumulative 10-year rate of adjudicated angina was 3.7% and for
heart failure was 2.9%, but was 9.6% and 6.9% for those with self-reported chest pain and shortness of breath.
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89.9

71.1

Dyslipidemia

Age ≥65 yrs

10.8

9.6

10.1

4.3

5.9

7.7

10.4

4.6

CVD Diagnostic Procedures

CVD = cardiovascular disease. Other abbreviations as in Table 2.

Values are %.

BMI ≥30

67.4

83.4

Hypertension

hsCRP >3 mg/l

76.9

High-risk FRS

70.3

70.8

CACS ≥400

kg/m2

86.6

Diabetes

CVD Medications

18.1

16.8

14.3

1.5

6.6

9.5

9.6

3.7

Outpatient Visits

1.3

1.4

1.6

1.6

1.5

2.2

4.6

1.7

Coronary Revascularization

2.4

2.0

2.9

2.7

2.6

3.8

4.6

3.5

CVD Hospitalizations

Proportion of 10-Year Costs Attributed to CVD Medications, Diagnostic Procedures, Outpatient Visits, Coronary Revascularization, and CVD
Hospitalizations
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